2023 World Conference on Lung Cancer (Posters)-EP17.04. Clinical Outcomes and Lack of Health Equity in Minority Patients with Unresectable Non-small Cell Lung Cancer (NSCLC) Treated with Durvalumab

EP17.04. Clinical Outcomes and Lack of Health Equity in Minority Patients with Unresectable Non-small Cell Lung Cancer (NSCLC) Treated with Durvalumab - PDF(Slides)

Back to course

Pdf Summary

The objective of this study was to compare the outcomes of concurrent chemoradiation followed by durvalumab in non-Hispanic Whites (NHW) versus minorities with advanced non-small cell lung cancer (NSCLC). The secondary objective was to compare the outcomes of this treatment in Hispanics versus African Americans with advanced NSCLC.<br /><br />Between January 2018 and March 2022, a total of 79 patients (42 NHW and 37 minorities) received durvalumab as consolidation therapy post-chemoradiation. Progression-free survival (PFS) was defined as the time from the last day of chemotherapy to progression, loss to follow-up, or death, while overall survival (OS) was defined as the time from the last day of chemotherapy to death or loss to follow-up. The median follow-up for the study was 25.6 months.<br /><br />The 24-month PFS rate was 44.6% in the NHW group compared to 38.4% in the minorities group, and the 24-month OS rate was 83.4% in the NHW group compared to 67.8% in the minorities group. When comparing Hispanics and African Americans, the 24-month PFS rate was 32.4% in the Hispanic group compared to 51.2% in the African American group, and the 24-month OS rate was 63.7% in the Hispanic group compared to 73.4% in the African American group.<br /><br />The study suggests that NHW patients have superior PFS and OS compared to minorities with advanced NSCLC. However, further research with a larger sample size is needed to confirm these findings. The study acknowledges limitations such as a small sample size and short follow-up period, which may affect the study's conclusions, particularly regarding overall survival.<br /><br />Overall, this study contributes to understanding the clinical outcomes and disparities in health equity among minority patients with unresectable NSCLC treated with durvalumab.

Asset Subtitle

Luis Raez

Meta Tag

Speaker Luis Raez

Topic Global Health, Health Services & Health Economics: Real World Data

Keywords

concurrent chemoradiation

durvalumab

non-Hispanic Whites

minorities

advanced non-small cell lung cancer

Hispanics

African Americans

progression-free survival

overall survival

health equity